SAN FRANCISCO: An Indian medical innovation has achieved a major global recognition with a new generation heart stent manufactured in India achieving a lower failure rate in high-risk patients against a US-made international market leader.
At a largely attended global conference of cardiologists, which concluded here on Wednesday, well-known Indian heart specialist, Dr Upendra Kaul, Chairman and Dean of Delhi’s Batra Hospital, presented the results of a trial in India named TUXEDO-2, which rigorously compared the new generation Indian-made heart stent, Supraflex Cruz, against the international market leader Xience of the USA.
Conducted across 66 Indian cardiology centres, the trial focused specifically on a highly complex patient population, such as patients with diabetes and advanced multi-vessel disease.
Eighty per cent of the participants had triple vessel disease, according to Dr Kaul, under whose leadership the trial was conducted.
The results were overwhelmingly positive for the Indian device, demonstrating that Supraflex Cruz was non-inferior to the established international standard.
